Federal Judge Certifies Class Actions in Takeda Antitrust Case Over Diabetes Drug Pricing

A New York federal judge has adopted a magistrate judge’s recommendation to certify two classes of direct purchasers and end payors in consolidated antitrust actions against Takeda Pharmaceuticals Co. The plaintiffs accuse Takeda of unlawfully inflating the price of its diabetes treatment, Actos, by delaying the entry of generic alternatives. This decision is expected to impact both the pharmaceutical industry and future antitrust litigation strategies. For more details, you can visit the original article on Law360.